Super-refractory status epilepticus in adults.

Epilepsy Seizures Standard operating procedure Standard operating procedure (SOP) Status epilepticus Super-refractory status epilepticus

Journal

Neurological research and practice
ISSN: 2524-3489
Titre abrégé: Neurol Res Pract
Pays: England
ID NLM: 101767802

Informations de publication

Date de publication:
22 Aug 2022
Historique:
received: 17 01 2022
accepted: 10 06 2022
entrez: 21 8 2022
pubmed: 22 8 2022
medline: 22 8 2022
Statut: epublish

Résumé

Super-refractory status epilepticus (SRSE) represents the culmination of refractory status epilepticus (RSE) and carries a significant risk of poor neurological outcome and high mortality. RSE is not defined primarily by seizure duration, but by failure to respond to appropriate antiseizure treatment. SRSE is present when a RSE persists or recurs after more than 24 h of treatment with anesthetics. No evidence-based treatment algorithms can be provided for SRSE. Therefore, we propose a pragmatic standard operating procedure (SOP) for the management of SRSE that addresses the existing uncertainties in the treatment of SRSE and provides options for resolution and decision-making. First, we recommend the assessment of persistent seizure activity and the evaluation of differential diagnoses to confirm correct diagnosis. Relevant differential diagnoses include psychogenic non-epileptic seizures, hypoxic, metabolic, or toxic encephalopathies, and tetanus. During SE or in severe encephalopathies, a so-called electroclinical ictal-interictal continuum may occur, which denotes an intermediate stage that cannot be defined with certainty as ictal or interictal by EEG and should not lead to harmful overtreatment. Because both prognosis and specific treatment options depend crucially on the etiology of SRSE, the etiological evaluation should be performed rapidly. When SRSE is confirmed, various pharmacological and non-pharmacological treatment options are available. We provide a pragmatical SOP for adult people with SRSE.

Identifiants

pubmed: 35989337
doi: 10.1186/s42466-022-00199-4
pii: 10.1186/s42466-022-00199-4
pmc: PMC9394073
doi:

Types de publication

Journal Article

Langues

eng

Pagination

35

Informations de copyright

© 2022. The Author(s).

Références

Epilepsy Behav. 2016 Jan;54:40-6
pubmed: 26645799
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
Neurocrit Care. 2021 Dec;35(3):631-639
pubmed: 34286464
Eur J Neurol. 2022 Feb;29(2):626-647
pubmed: 34661330
Neurology. 2014 Nov 18;83(21):1978-85
pubmed: 25355830
Epilepsia. 2013 Sep;54 Suppl 6:28-9
pubmed: 24001066
Neurocrit Care. 2015 Apr;22(2):273-82
pubmed: 25412806
Seizure. 2017 Apr;47:51-65
pubmed: 28288363
Seizure. 2017 Aug;50:19-32
pubmed: 28600921
Seizure. 2016 Feb;35:23-32
pubmed: 26789495
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Epilepsy Curr. 2021 Mar 10;:1535759721999670
pubmed: 33719651
Epilepsy Behav. 2019 Dec;101(Pt B):106466
pubmed: 31462385
J Clin Neurophysiol. 2018 Jul;35(4):274-278
pubmed: 29979285
N Engl J Med. 2016 Dec 22;375(25):2457-2467
pubmed: 28002714

Auteurs

Michael P Malter (MP)

Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. michael.malter@uk-koeln.de.

Janina Neuneier (J)

Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.

Classifications MeSH